 DecisionBase PDFs --
2008
 Overview:
Bipolar disorder (BPD) is a chronic and debilitating
psychiatric illness characterized by recurrent episodes of mania, depression,
or a mixture of both depression and mania. The BPD market offers significant drug
development opportunities due to high unmet need and slim competition in the
pipeline. Approval of new atypical antipsychotics for this indication offers
the best chance of differentiation from most currently available therapies.
Nonetheless, physicians await novel therapies with improved efficacy in BPD.
Questions Answered in This Report:
 A drug’s performance on at least six efficacy end points,
including efficacy in bipolar mania at 3 weeks and efficacy in bipolar
depression at What are the key primary and secondary clinical trial end points with
which new therapies are evaluated? How do psychiatrists weight efficacy
measures and other drug attributes in their prescribing decisions for bipolar
depression?
Quetiapine (AstraZeneca’s Seroquel) is the 2006 major-market
sales leader for BPD. How will emerging agents fare against quetiapine? Will
emerging therapies offer improvements in the efficacy end points and drug
attributes that are most influential in physician prescribing decisions? Which
emerging therapies, if any, are best positioned to challenge the market-leading
status of quetiapine?
By 2011, quetiapine XR (AstraZeneca’s Seroquel XR) will
emerge as the gold-standard therapy in our drug comparator model because its clinical profile is superior to that of the
current therapies evaluated in this study. On what clinical attributes is
quetiapine XR most differentiated from its competitors? Which current therapies
are at greatest risk of being replaced by quetiapine XR?
Scope:
Key drug development opportunity tested in our target
product profiles for BPD: A therapy that carries a lower risk of weight gain
than quetiapine and has both antimanic and antidepressant effects for the
treatment of BPD.
Physicians surveyed for this study: 60 U.S. psychiatrists.
Comprehensive List of Therapies Included in Our Research and
Modeling
Current therapies:
- Quetiapine (AstraZeneca’s Seroquel)
- Olanzapine (Eli Lilly’s Zyprexa)
- Lamotrigine (GlaxoSmithKline’s Lamictal)
- Divalproex ER (Abbott’s Depakote ER)
- Lithium (GlaxoSmithKline’s Eskalith, Solvay’s
Lithobid/Liskonum/Quilonum, Taisho’s Limas, generics)
Emerging therapies:
- Quetiapine XR (AstraZeneca’s Seroquel XR)
- Paliperidone (Janssen’s Invega)
- Bifeprunox (Solvay/Lundbeck)
- Asenapine (Schering-Plough)
- Licarbazepine (Novartis)
About DecisionBase
Bipolar Disorder: Although Bipolar Mania Is a Crowded
Market, Physicians Continue to Demand Better Treatment is a DecisionBase 2008 study
from Decision Resources. DecisionBase 2008 combines market forecasts with
clinical and commercial end points to assess market share projections in 35
indications. These outputs are driven by quantitative and qualitative primary
research. DecisionBase 2008 provides detailed market share, patient share, and
price-per-day projections for emerging drugs in development. The market share
projections are based on prescriber surveys that compare physicians’
expectations of a potential target product profile with an emerging product
profile of the leading drugs in development.
|
